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For metastases in the central nervous system, angiogenesis enhances metastatic
potential and promotes progression. Primary factors which drive vessel growth are
vascular endothelial growth factor (VEGF) and angiopoietin-2. Preclinical models show
inhibition of either factor reduces metastases spread and inhibits growth. This work sets
out to answer two questions in a preclinical mouse model. First, whether the combined
inhibition of VEGF and angiopoietin-2, reduces passive permeability and limits drug
uptake into brain metastases; and second, whether this inhibition reduces metastases
burden in brain. We observed combinatorial inhibition of VEGF and angiopoietin-2,
decreased (p < 0.05) angiogenesis and vascular branching in an aortic ring assay and
decreased (p < 0.05) endothelial wound closure times. Using a brain metastases of
breast cancer model (induced by intracardiac injections of brain seeking MDA-MB-
231Br cells or 4T1Br cells), we observed, similar to VEGF, angiopoetin-2 expression
correlates to increased angiogenesis (p < 0.05) and increased lesion permeability. To
determine efficacy, animals were administered bevacizumab plus L1-10 (angiopoietin
inhibitor) twice per week until neurological symptoms developed. Lesion permeability
significantly decreased by ∼50% (p < 0.05) compared to untreated lesions, but
remained ∼25% greater (p < 0.0%) than brain. In subsequent experiments, animals
were administered similar regimens but sacrificed on day 32. The number of metastatic
lesions developed was significantly (p < 0.001) reduced in the bevacizumab group
(56%) and combination group (86%). Lesions’ size was reduced in bevacizumab
treated lesions (∼67%) and bevacizumab and L1-10 treated lesions (∼78%) developing
area < 0.5 mm2. In summary, combinatorial inhibition of VEGF and angiopoietin reduces
lesion permeability and brain metastatic burden.
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INTRODUCTION
Current treatment options of brain and CNS metastases are
modest and only expand survival approximately 4 months
(Labidi et al., 2009; Pestalozzi, 2009; Goldfarb et al., 2011).
Most patients (70%) die within 1 year (Pestalozzi, 2009).
Previously, a preclinical model analyzing 2,000 brain metastases
of breast cancer found that, while nearly all lesions had increased
permeability, only 10% of the lesions were permeable enough to
allow drug to accumulate at concentrations which were sufficient
to induce cytotoxicity (Lockman et al., 2010). The study suggested
that the blood–brain barrier (BBB) and the blood-tumor barrier
(BTB) present a significant obstacle in the treatment of brain
metastases by limiting drug uptake to subtherapeutic levels
(Lockman et al., 2010).
The BBB serves as a functional and structural barrier,
limiting passive diffusion of hydrophilic and charged compounds
into brain (Abbott et al., 2009). With the occurrence of
brain metastases, new vessels are either sprouted from existing
BBB vessels or potentially created de novo (Groothuis, 2000;
Pestalozzi, 2009). BTB vascular structure is distinctive compared
to the vascular structure of BBB. BTB has increased permeability,
different pattern of transporters regulation, and possibly
downgraded blood flow (Hiesiger et al., 1986; Bronger et al., 2005;
Gerstner and Fine, 2007).
In metastases, vascular destabilization and accompanying
angiogenesis enhance tumor growth (Folkman, 1990), upregulate
growth factors such as vascular endothelial growth factor (VEGF)
and Ang-2 (Veeravagu et al., 2007), metastatic potential (Fidler
and Ellis, 1994; Claffey et al., 1996), and correlate with poor
patient outcome (Weidner et al., 1992; Meitar et al., 1996; Uzzan
et al., 2004). A primary driver of angiogenesis is VEGF, which is
secreted by tumor cells in response to decreased vessel density
and hypoxia. VEGF is highly expressed in breast, colorectal, and
non-small cell lung carcinoma (Lee et al., 2007; Kadota et al.,
2008; Barresi et al., 2010). A secondary driver of angiogenesis is
angiopoietin-2 (Ang-2), which activates in response to hypoxia
and induces vessel destabilization upon binding the Tie2 receptor
(LaManna et al., 2004; Chae et al., 2010). Both VEGF and Ang-2
have been shown to independently induce angiogenesis (Blacher
et al., 2001; Teichert-Kuliszewska et al., 2001).
Importantly, VEGF and Ang-2 have been shown to
synergistically act to induce endothelial destabilization, increase
vascular branching (Chae et al., 2010; Hashizume et al., 2010;
Morrissey et al., 2010), and increase angiogenesis (Holash et al.,
1999; Zhang et al., 2003). In addition, the two growth factors
independently induce formation of endothelial branches in
ex vivo aortic ring assays, suggesting an angiogenic effect on
perivascular cells as well (Nicosia et al., 1997; Iurlaro et al., 2003).
Inhibition of VEGF with bevacizumab, a monoclonal
antibody which binds to the VEGF ligand preventing receptor
phosphorylation, has been shown to reduce angiogenesis in
tumors (reducing vessel branching and growth) (Borgstrom et al.,
1996), resulting in slower tumor development (Zhang et al., 2002;
Holloway et al., 2006; Roland et al., 2009), reduced metastasis
development (Ellis et al., 2000; Verheul et al., 2007), and
improved drug delivery through vascular normalization (Tong
et al., 2004; Jain, 2005). Several studies evaluating bevacizumab
in glioblastoma patients demonstrated that pharmacological
treatment reduced brain edema and intracranial pressure, leading
to a small increase in progression-free survival (Vredenburgh
et al., 2007; Verhoeff et al., 2009). However, a review evaluating
bevacizumab in CNS tumors (clinical and preclinical glioma
models) showed that bevacizumab decreased the permeability
of the contrast agent gadolinium at the BTB (Thompson et al.,
2011). Currently, the only bevacizumab data available for brain
metastases of breast cancer are two studies which report only the
relative risk of hemorrhagic events when taking the drug (Labidi
et al., 2009; Besse et al., 2010).
Similarly, the peptide-Fc fusion L1-10 has been shown
to block Ang-2 from binding the Tie2 receptor, which also
decreases angiogenesis and tumor growth in both prostate cancer
(Morrissey et al., 2010) and gliomas (Villeneuve et al., 2008).
Additionally, the administration of L1-10 in the presence of
different concentrations of cytotoxic drugs increased anti-tumor
activity (Brown et al., 2010). Therefore, it has been hypothesized
that simultaneous inhibition of VEGF and Ang-2 will decrease
tumor growth and/or development (Bergers et al., 2003; Erber
et al., 2004; Chae et al., 2010).
In this report, we inhibit both VEGF and angiopoetin-2
in an experimental brain metastases model to determine how
this affects metastatic burden in brain. First, we demonstrate
that VEGF and Ang-2 act cooperatively to induce angiogenesis
in vitro; next, we identify the development of hypoxic
brain metastases, which exhibit Ang-2 activation. We then
evaluated the effects of bevacizumab and L1-10 on metastases
formation and permeability of experimental brain metastases.
To accomplish this, we injected ∼175 k brain seeking cells
(MDA-MB-231-BR or 4T1-BR5 overexpressing Her-2) into the
peripheral circulation and allowed experimental brain metastases
to develop (Lockman et al., 2010). Ten days after injection of
cells, bevacizumab (10 mg/kg) (Lucio-Eterovic et al., 2009) and
L1-10 (4 mg/kg) (Villeneuve et al., 2008) were administered in
experimental groups. After neurological symptoms developed,
we administered 14C-AIB or 14C-paclitaxel intravenously to
determine permeability and drug uptake. We observed that
both 14C-AIB permeability and 14C-paclitaxel drug uptake was
significantly reduced. Of importance, we observed a reduction
in the number of metastatic lesions in bevacizumab and
bevacizumab+ L1-10 treated groups.
These data suggest that combinatorial therapy of VEGF
blockade and Ang-2 inhibition may be an effective strategy
to reduce brain metastases formation. However, this dual
target approach also reduced permeability and drug uptake in
established brain metastases, which warrants caution in the
therapeutic use of VEGF and Ang-2 inhibition.
MATERIALS AND METHODS
Chemicals
14C-AIB (specific activity: 55 mCi/mmole) was purchased
from American Radiolabeled Chemicals (St. Louis, MO, USA).
14C-Paclitaxel (specific activity 70 mCi/mmole) was obtained
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from Moravek Biochemicals and Radiochemicals (Brea, CA,
USA). The peptide-Fc fusion, L1-10 was a kind gift from Amgen
(Thousand Oaks, CA, USA), and bevacizumab (AvastinTM)
was purchased from Genentech (San Francisco, CA, USA).
HypoxyprobeTM kit was purchased from HPI Inc. (Burlington,
MA, USA). All other chemicals are of analytical grade and were
purchased from Sigma (St. Louis, MO, USA).
Animals
Female NuNu mice (25–30 g) were obtained from Charles River
Laboratories (Kingston, NY, USA) and used for the metastasis
experiments in this study. Male Fisher 344 rats (300–350 g)
also from Charles River Laboratories were used for aortic ring
assays. All studies were approved by the Animal Care and Use
Committee at Texas Tech University Health Sciences Center, and
conducted in accordance with the 1996 NIH Guide for the Care
and Use of Laboratory Animals.
Cell Culture
Human metastatic breast cancer over-expressing Her2 cells
(MDA-MB-231-BR-Her2) and 4T1-BR5 murine mammary
carcinoma cells were chosen for the experimental brain
metastases model. Murine brain endothelial cell cultures
(bEND5) were cultured in DMEM medium supplemented with
10% FBS, 1% non-essential amino acids, 1% sodium pyruvate,
1% penicillin/streptomycin/amphotericin B, and 2% 200 mM
L-glutamine. All cells were used in passages 1–10 and maintained
at 37◦C with 5% CO2.
Development of Metastases and
Administration of Inhibitors
Mice were anesthetized and inoculated with breast cancer cell
lines (MDA-MB-231-BR-Her2: 1.75× 105 and 4T1-BR5: 5× 104)
in the left cardiac ventricle with the use of a stereotaxic device.
Tumor cells were confirmed to seed in the brain via an IVIS
Lumineer XV in vivo animal imager (Caliper Life Sciences, Inc.,
Part of PerkinElmer, Inc.). Tumors were allowed to develop
over ∼4–6 weeks or until neurological symptoms of weight loss,
lethargy, or paralysis appeared. As metastases seeded the brain,
treatments were administered beginning on day 10 [Bevacizumab
(10 mg/kg, i.p., twice weekly) (Lucio-Eterovic et al., 2009) and
L1-10 (4 mg/kg diluted in PBS, s.c., twice weekly) (Villeneuve
et al., 2008)] and continued until day 32, at which point animals
were euthanized as mentioned.
Injection of Vascular Markers and
14C-Paclitaxel
In permeability studies, on day 32, 14C-AIB (25 µCi/animal;
American Radiolabeled Chemicals) was injected intravenously
(10-min circulation), animals were sacrificed, brain tissue was
removed and placed in isopentane (−65◦C). For evaluation of
paclitaxel uptake, 14C-paclitaxel (25 µCi/animal) was injected
and allowed to circulate for 120 min, followed by euthanasia
and rapid removal of brain tissue for immediate freezing
in isopentane. For hypoxia evaluation, animals were injected
intravenously with pimonidazole hydrochloride (60 mg/kg,
HypoxyprobeTM) and allowed to circulate for 1 min. Afterward,
tissues were processed, and immunofluorescence was performed.
Brains were sliced at 20 µm thickness using a cryostat (Leica
Microsystems, Wetzler, Germany). Direction of brain slice
cutting was rostral (anterior) to caudal (posterior). Sections
were mounted on glass slides, air dried, and stored at −80◦C.
The distribution of 14C-AIB and 14C-paclitaxel in brain and
metastases was measured by quantitative autoradiography.
Immunofluorescence
Tissues were rehydrated briefly in phosphate buffered saline
(PBS) and fixed in cold 4% paraformaldehyde (4◦C) for 30 min.
After three washings of PBS, the slides were then covered in 1%
sodium dodecyl sulfate for 5 min and rinsed again with PBS.
Slides were submerged in blocking solution of 10% goat serum
in PBS for 30 min at room temperature. Primary antibodies
diluted in 5% goat serum: CD31 (Clusters of Differentiation
31) (BD Pharmingen, San Diego, CA, USA), Ang-2 (Abcam,
San Francisco, CA, USA), HypoxyprobeTM rabbit antisera (HPI
Inc, Burlington, MA, USA) were incubated overnight at 4◦C
followed by washing. Sections were covered in 0.03% hydrogen
peroxide + 0.1% sodium azide for 10 min and subsequently
washed. After a second blocking with 10% goat serum for
30 min, slides were incubated with secondary antibodies diluted
in 5% goat serum: Alexa Fluor R© 594 (red) and Alexa Fluor R©
488 (green). DAPI was added to this solution at 1 mg/mL
(Invitrogen, 4′,6-diamidino-2-phenylindole, dilactate) and slides
were incubated for 1 h at room temperature.
Migration Assay
Cell migration was evaluated with an in vitro wound healing
assay. The endothelial cells (bEND5) were cultured in 24 well
plates (DMEM supplemented with 10% FBS) to confluence and
serum starved for 1 h prior to beginning treatments. After
obtaining quiescence, the cultures were wounded with a 0.1 cm3
pipette tip in one direction. To remove cellular debris, the
wounded cells were washed with PBS. Cells were incubated
with DMEM (supplemented with 1% FBS) containing various
concentrations of Ang-2 (recombinant human Angiopoietin-
2, R&D Systems), VEGF (recombinant human VEGF, R&D
Systems), L1-10 (Amgen), and/or bevacizumab (AvastinTM
Genentech) at 37◦C. Images were taken at initial wound healing,
24, 48, and 72 h, and percentage of wound closure was calculated.
Rat Aorta Model of Angiogenesis
Male Fisher 344 rats were anesthetized and a mid-line incision
was made to reveal the thoracic cavity. The diaphragm was cut
and the heart and lungs were removed. The aorta was then excised
and placed in 4◦C DMEM medium and sectioned into 3 mm
segments. Aortic rings were kept on ice until they were embedded
into approximately 200 µl of matrigel (BD Biosciences) in 24
well plates. Rings were kept at 37◦C for 1 h and 50 µl of
matrigel was placed on top of the rings. Rings were allowed
to sit for 24 h in DMEM containing 1% FBS at 37◦C before
treatment was initiated and time point zero photos were taken.
Rings were incubated with various concentrations of Ang-2,
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VEGF, bevacizumab, and/or L1-10 in DMEM containing 1% FBS.
Images were taken at 24, 48, and 72 h. Branching morphogenesis
was calculated by counting the number of angiogenic branches in
three sections (500 µm in size) per ring.
Assessment of Metastases Development
To evaluate the number and size of metastases developed, ten
microscope slides containing five brain slices (20 µm/slice) were
randomly selected per animal (n = 3–6 animals per treatment
group). Metastatic lesions were identified by eGFP fluorescence
and then counted in one brain slice per slide, being careful to
count only individual tumors rather than large lesions, which
might be present in multiple slides. Comprehensive digital
microscopy software (3i SlidebookTM 5.0) was used to calculate
lesion area.
Statistical Analysis
Student’s t-test was used to determine statistical significance
in aortic ring assays, migration assays, and the difference
in Ang-2 expression between permeable and non-permeable
lesions. Linear regression analysis was used to determine the
relationship between 14C-AIB permeability independently with
Ang-2 expression and metastasis size. One-way ANOVA followed
by Bonferroni’s multiple comparisons test was used to evaluate
significance of AIB brain space, the number of metastases
developed in each treatment group, and the percentage of
metastases in each size group. All differences were considered
statistically significant at p < 0.05. Data are reported as
Mean ± Standard Error of Mean (SEM) (GraphPad Prism R©
version 7.0).
RESULTS
In vitro Angiogenesis Assays
To confirm that VEGF and Ang-2 synergistically induced
angiogenesis in vitro, which could be inhibited with bevacizumab
and L1-10, we used aortic ring and wound healing assays.
Briefly, aortic ring growth (Figure 1A) averaged 6.4 ± 1.5,
61 ± 9.4, and 148 ± 10 endothelial branches at 24, 48, and
72 h, respectively. A significant increase (p < 0.01) in branching
was seen at 48 and 72 h (211 ± 18.2 and 303 ± 47.9 branches)
in wells treated with the combination of Ang-2 and VEGF
as compared to control. Upon the addition of bevacizumab,
branching remained unchanged at 24 h (54 ± 10 branches)
but was reduced (p < 0.05) at 48 h (161 ± 9.8) and 72 h
(241 ± 27 branches). The addition of L1-10 further reduced
endothelial branching (p < 0.05) at all three time points.
Following the aortic ring assays, we completed wound healing
assays (Figure 1B) to compliment the aortic ring data. Our initial
experiments demonstrated that the most effective combinatorial
concentration of VEGF and Ang-2 to create wound closure
was 10 ng/mL for Ang-2 and 5 ng/mL for VEGF (data not
shown). Furthermore, the combinational treatment of VEGF and
Ang-2 increased wound closure (p < 0.01) at 24 (30% ± 4.8),
48 (57% ± 7.3), and 72 h (76% ± 8.3) compared to control
values (21% ± 1.9, 48 ± 3.9, and 66 ± 4.9), Ang-2 values
(30.06% ± 4.779, 56.92 ± 7.283, and 74.59 ± 8.283) and VEGF
values at (28.66% ± 4.9, 57.92 ± 8.8, and 70.86 ± 10.22)
at the same respective times. The addition of bevacizumab
resulted in a significant decrease (p < 0.05) in noted cell
migration. To a lesser extent, this was also seen with the
FIGURE 1 | Vascular endothelial growth factor (VEGF) and Ang-2 promote angiogenesis and can be modulated by inhibition. The endothelial branching
observed from in vitro aortic ring angiogenesis assays in the presence of VEGF (10 ng/mL) + Ang-2 (100 ng/mL) and the addition of bevacizumab (20 µg/mL) and
L1-10 (6.5 µg/mL) for 24, 48, and 72 h duration of treatment (A). An increase in endothelial branching compared to control is denoted by (∗). A reduction in
endothelial branching compared to VEGF + Ang-2 is denoted by (†). Wound closure of bEND5 cells in the presence of Ang-2 (10 ng/mL) + VEGF (5 ng/mL) and the
addition of bevacizumab (20 µg/mL) and L1-10 (6.5 µg/mL) in comparison to Ang-2 (10 ng/mL) and VEGF (5 ng/mL) over 24, 48, and 72 h (B). An increase in
percent wound closure relative to control is denoted by (∗) and a decrease in wound closure relative to Ang-2 + VEGF is denoted by (†). Statistical evaluation was
determined by student’s t-tests; ∗ and † for p < 0.05, ∗∗ and †† for p < 0.01, ∗∗∗ and ††† for p < 0.001 and ∗∗∗∗ and †††† for p < 0.0001.
Frontiers in Pharmacology | www.frontiersin.org 4 April 2017 | Volume 8 | Article 193
fphar-08-00193 April 7, 2017 Time: 17:20 # 5
Bohn et al. VEGF and Angiopoietin-2 in Brain Metastases
combination of bevacizumab and L1-10. The in vitro studies
confirm the angiogenic effects of VEGF and Ang-2 on endothelial
cells.
Metastases Are Hypoxic
In our second set of experiments, we set out to determine if
hypoxia was present in the lesions, which would activate Ang-2
expression, increasing angiogenesis. We observed that nearly
all lesions have some degree of hypoxia using HypoxyprobeTM
(Pimonidazole HCl) staining; however, regions of hypoxia
appeared heterogeneous between all lesions irrespective of
metastasis size (data not shown). The variability in tumor
vascular density could result in a larger lesion containing
less pimonidazole HCl than the smaller lesion (Groothuis,
2000).
Ang-2 Expression in Metastatic Lesions
Because increases in VEGF expression have been reported
to correlate with elevated blood-tumor barrier permeability
of metastatic lesions, we wanted to determine the relative
expression of Ang-2 in an experimental brain metastases of
breast cancer model. Brain slices were stained with anti-Ang-
2 and anti-CD31 antibodies. In addition, metastatic lesions
were categorized either “non-permeable” or “permeable” based
upon whether changes in 14C-AIB permeability exceeded the
mean permeability of 14C-AIB in normal brain plus three
standard deviations. Ang-2 staining was higher in permeable
lesions than non-permeable in both models (Figures 2A–
E). The presence of Ang-2 within metastatic lesions with
higher permeability agrees with previous studies reporting
the role of Ang-2 in vascular destabilization (Zhang et al.,
2003).
In vivo Inhibition of VEGF and Ang-2
Decreases 14C-AIB Permeability and
Drug Uptake
To determine the effects of VEGF and Ang-2 inhibition on
blood-tumor barrier permeability in vivo, mice were injected
with 1.75 × 105 brain seeking cells followed by treatment
of bevacizumab in combination with L1-10 10 days after
inoculation. Representative images of eGFP labeled metastatic
lesions in a treated brain are shown in Figure 3A and a
representative autoradiograph of 14C-AIB permeability is shown
in Figure 3B. In the treatment groups 14C-AIB permeability
was significantly reduced to only ∼fourfold above control brain
(Figure 3C). The highest observed fold change in the treatment
group was 6.74 (Figure 3D) (compared to 33.7 in non-treated
metastases).
To determine if combinatorial therapy would similarly
decrease brain uptake of paclitaxel, we repeated the studies
of administering bevacizumab and L1-10 during metastasis
development. On day 32, animals were administered
14C-paclitaxel 2 h prior to euthanasia and processed as described.
14C-Paclitaxel concentrations were significantly decreased by
combination therapy of bevacizumab and L1-10 and standalone
therapy of bevacizumab to a mean concentration of 202 and
FIGURE 2 | Expression of angiopoietin-2 is greater in lesions with
higher permeability. Brain slices from un-treated metastases bearing
animals were stained for the hypoxia induced vascular destabilizing protein
Ang-2. Ang-2 expression in MDA-MB-231-BR-Her2 metastases is shown in
non-permeable (A) and permeable (B) metastatic lesions. Representative
images in the 4T1-BR5 model are shown in a lesion with low permeability (C)
and a lesion with high permeability (D). Ang-2 (red), CD31 (green), DAPI (blue).
Ang-2 intensity in permeable and non-permeable lesion in both preclinical
models of brain metastases of breast cancer (E). Permeable lesions
demonstrated greater Ang-2 expression than non-permeable in both models,
with a >2-fold increase in the MDA-MB-231-BR-Her2 model, indicating the
presence of vascular destabilization. Scale bar = 25 µm. Statistical
significance was determined using Student’s t-test to determine difference in
Ang-2 expression between the two permeability groups within each model
(∗∗∗ for p < 0.001).
163 ng/g, respectively (Figure 4) compared to untreated animals
(276 ng/g, P < 0.05) (Lockman et al., 2010). Some lesions had
uptake of more than 514 ng/g while others showed very little
uptake 47 ng/g (compared with a range of 14.9 ng/g to 1961 ng/g
in un-treated metastases).
Importantly, fewer metastatic lesions developed (p < 0.001)
in the combinatorial bevacizumab and L1-10 group (10 ± 4)
than what was observed for either bevacizumab treatment
(31.6 ± 6) or untreated controls (72 ± 10) (Figure 5).
Furthermore, the percentage of large metastatic lesions present in
the combinatorial group (7.7 ± 5) decreased (p < 0.05) relative
to the percentage of large lesions observed in the bevacizumab
treated group (14.6 ± 4) and significantly less (p < 0.05) than
un-treated controls (34.6± 8).
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FIGURE 3 | Treatment of bevacizumab and L1-10AIB during metastasis development decreases permeability of 14C-AIB, which correlates with
metastasis size. Representative brain slice image of enhanced green fluorescent protein (eGFP) labeled lesions (A) and corresponding quantitative autoradiography
(QAR) image (B) with 14C-AIB distribution. The percent brain space of 14C-AIB in normal brain and metastases (C). Fold-increase in permeability with metastasis
size reveals a weak correlation in bevacizumab plus L1-10 treated lesions (n = 65, r2 = 0.162, p < 0.05) (D). Statistical significance was determined using ANOVA
followed by Bonferroni’s multiple comparisons test for AIB brain space percentage, and linear regression analysis for fold increase in permeability versus lesion size
(∗∗∗ for p < 0.001).
FIGURE 4 | Brain uptake of 14C-paclitaxel in brain metastases after bevacizumab treatment. Bevacizumab reduces (p < 0.05) metastasis paclitaxel uptake
to a mean of 163 ng/g, ranging from 7.76 to 788 ng/g (n = 81) as compared to our previously reported value of 276 ng/g ranging from 2.56 to 1768 (Lockman et al.,
2010). In addition, there was a strong correlation with Texas Red 3 kDa dextran permeability (r2 = 0.72, p < 0.001) (A). In addition, paclitaxel concentrations in
metastases from the bevacizumab group showed a weak correlation with lesion size (r2 = 0.071, p < 0.05) (B).
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FIGURE 5 | Bevacizumab and L1-10 treatment reduces metastatic
burden in brain. Representative images of MDA-MB-231-BR-Her2
non-treated metastatic brain (A), bevacizumab treated brain (B), and
bevacizumab + L1-10 treated brain (C). Bevacizumab (10 mg/kg) or
bevacizumab + L1-10 (4 mg/kg) was administered on day 10 after inoculation
(Continued)
FIGURE 5 | Continued
with cancer cells and the number of metastatic lesions developed was
significantly (p < 0.001) reduced in the bevacizumab alone group (56%) and in
the combination group (86%) (D). Treatment also reduced lesion size with
67% ± 1 of bevacizumab treated lesions and 78% ± 10 of
bevacizumab + L1-10 treated lesions developing area < 0.5 mm2. Data
illustrate a significant reduction in metastatic burden with simultaneous
inhibition of the VEGF/angiopoietin-2 pathway. Significance was determined
using ANOVA analysis followed by Bonferroni’s multiple comparisons test;
∗ for p < 0.05, ∗∗ for p < 0.01 and ∗∗∗ for p < 0.001.
DISCUSSION
In this study, we demonstrate that Ang-2 and VEGF work
cooperatively to induce angiogenesis. We also show experimental
brain metastases have activated Ang-2, that Ang-2 is present at
the BTB vasculature, and blockade of the VEGF/Ang-2 pathway
results in significant reductions in permeability, drug uptake, and
metastatic burden.
Herein, we demonstrate that VEGF and Ang-2 have a
combinational effect on angiogenesis, similar to previous reports
(Chae et al., 2010; Hashizume et al., 2010; Morrissey et al., 2010).
Additionally, we demonstrate that there was a greater inhibition
of vessel branching in the presence of both bevacizumab and
L1-10, indicating a potential role of L1-10 affecting several
aspects of angiogenesis including tubule formation, endothelial
cell proliferation, and migration of endothelial cells in monolayer.
This is consistent with data from other reports demonstrating
VEGF and Ang-2 can act to induce the formation of vascular
tubes (Asahara et al., 1998; Lobov et al., 2002).
Hypoxia plays a role in several stages of tumor progression
such as angiogenesis and metastatic invasion (Lu et al., 2010).
Clinically, several cancer types such as lung, colon, and breast
have been shown to contain regions of hypoxia compared to
their adequately perfused counterparts (Zhong et al., 1999).
Areas of hypoxia were also noted in bone metastases of breast
cancer (Hiraga et al., 2007) and in animal models of gliomas
(Bernsen et al., 2000). Data in our second set of experiments
looking at hypoxia in preclinical brain metastases of breast
cancer, agree with the clinical and other preclinical data that
nearly every lesion has some degree of hypoxia whether or not it
is adequately perfused (Brown, 1990; Hoückel and Vaupel, 2001;
van Laarhoven et al., 2006; Lu et al., 2010).
Hypoxia has been shown to up-regulate Ang-2 mRNA in
endothelial cells (Jones, 2003) as well as in rat brain tissue
(Mandriota et al., 2000). Herein, we observed the presence
of Ang-2 in the vasculature was associated with nearly all
lesions identified in both preclinical models. Of interest,
we observed elevated expression of Ang-2 in lesions with
greater vascular permeability. Ang-2 up-regulation results from
the induction of cyclooxygenase-2 (COX-2) enzyme, which
metabolizes arachidonic acid to prostaglandin E2 in brain
endothelial cells (LaManna et al., 2004). Clinically, aggressive
gliomas have been shown to express greater levels of Ang-2
than low-grade gliomas; and in vitro studies suggest Ang-2
mRNA expression increases in human glioma cells in response
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to hypoxia (Koga et al., 2001). Under healthy conditions, Ang-
2 is barely detectable in brain (Tait and Jones, 2004); however,
VEGF has been shown to induce Ang-2 expression in brian
(Mandriota and Pepper, 1998), resulting in both destabilization
of brain vasculature and altering the integrity of the endothelium.
In this study, we demonstrate that lesions that have
greater permeability in the 4T1BR model have increased
Ang-2 expression. This data are consistent with literature
demonstrating that during angiogenesis, Ang-2 is released
from tumor cells (Morrissey et al., 2010) and binds the
endothelial cell Tie2 receptor, which causes pericytes to pull away
from the endothelium, resulting in a destabilized vasculature
(Ahmad et al., 2001; Zhang et al., 2003; LaManna et al., 2004;
Scharpfenecker et al., 2005). Vascular destabilization is further
compounded when there is a decreased oxygen supply, which
induces the dimerization of HIF-1α to HIF-1β, to form the HIF-1
complex. This dimer then translocates to the nucleus and acts as
a transcription factor for VEGF and matrix metalloproteinases,
which help to degrade the basement membrane (Zagzag et al.,
2000; Kaur et al., 2005).
In our next set of experiments, we attempted to demonstrate
that inhibition of VEGF with bevacizumab and Ang-2 with L1-10
results in decreased permeability and drug uptake. We observed
that the combinatorial therapy resulted in a marked decrease
in vascular permeability to 14C-AIB (∼100 Da) from ∼30-fold
for lesions in untreated controls to ∼5-fold in the treatment
group. We then evaluated whether the combinatorial therapy
would also reduce paclitaxel uptake in the metastatic lesions.
As expected, we saw a decreased uptake of paclitaxel within all
lesions of combinatorial treatment groups (mean concentration
of 202 ng/g, ranging from 47.1 to 514 ng/g) compared to the
untreated controls (mean concentration of 392 ng/g, ranging
from 14.9 to 1961 ng/g). Previous studies using identical models
identified paclitaxel concentrations in brain metastases must
exceed 1000 ng/g to induce apoptosis in the metastases (Lockman
et al., 2010). In the current study, paclitaxel concentrations in
both preclinical models failed to reach effective concentrations.
Previous reports have demonstrated that inhibition of VEGF
results in slower tumor progression (Zhang et al., 2002; Holloway
et al., 2006; Roland et al., 2009) and reduced metastasis
development (Ellis et al., 2000; Verheul et al., 2007). Similarly,
Ang-2 inhibition has been shown to slow prostate cancer
(Morrissey et al., 2010) and glioma progression (Villeneuve et al.,
2008). Therefore, we set out to determine whether inhibition
of VEGF and Ang-2 by dual administration of bevacizumab
plus L1-10, respectively, would reduce metastasis colonization
and progression. We observed a significantly smaller number
of lesions in the combinatorial therapy group (n = 10 ± 4)
compared to the bevacizumab treated group (n = 31.6 ± 6) and
compared to the untreated controls (n = 72 ± 10). These data
suggest that simultaneous inhibition of VEGF and Ang-2 may be
effective for the prevention of brain metastases.
In summary, we demonstrate an integral role of Ang-2
and VEGF in angiogenesis and brain metastases progression.
While simultaneous inhibition of these two angiogenic factors
may have significant potential in reducing the formation of
experimental brain metastases, this strategy should not be used in
established metastases since it significantly restricts permeability
and drug uptake. Further work should be done to determine
if simultaneous inhibition of the VEGF/Ang-2 pathway can
be effectively employed to reduce brain metastasis formation
altogether.
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